Literature DB >> 31701330

Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.

M De Groot1, A Compter2, A J De Langen3, D Brandsma2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31701330     DOI： 10.1007/s00415-019-09587-4

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  13 in total

Review 1.  Susac syndrome: a report of four cases and a review of the literature.

Authors:  S M van der Kooij; M A van Buchem; O M Overbeek; G Dijkman; T W J Huizinga
Journal:  Neth J Med       Date:  2015-01       Impact factor: 1.422

Review 2.  Diagnostic criteria for Susac syndrome.

Authors:  Ilka Kleffner; Jan Dörr; Marius Ringelstein; Catharina C Gross; Yvonne Böckenfeld; Wolfram Schwindt; Benedikt Sundermann; Hubertus Lohmann; Heike Wersching; Julia Promesberger; Natascha von Königsmarck; Anne Alex; Rainer Guthoff; Catharina J M Frijns; L Jaap Kappelle; Sven Jarius; Brigitte Wildemann; Orhan Aktas; Friedemann Paul; Heinz Wiendl; Thomas Duning
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-10-25       Impact factor: 10.154

Review 3.  Characteristics of Susac syndrome: a review of all reported cases.

Authors:  Jan Dörr; Sarah Krautwald; Brigitte Wildemann; Sven Jarius; Marius Ringelstein; Thomas Duning; Orhan Aktas; Erich Bernd Ringelstein; Friedemann Paul; Ilka Kleffner
Journal:  Nat Rev Neurol       Date:  2013-04-30       Impact factor: 42.937

4.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

Review 5.  Susac's syndrome--pathogenesis, clinical variants and treatment approaches.

Authors:  Antonio Greco; Armando De Virgilio; Andrea Gallo; Massimo Fusconi; Rosaria Turchetta; Mario Tombolini; Maria Ida Rizzo; Marco de Vincentiis
Journal:  Autoimmun Rev       Date:  2014-04-12       Impact factor: 9.754

6.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

Review 7.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

Authors:  Sandip Pravin Patel; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2015-02-18       Impact factor: 6.261

Review 8.  Immune checkpoint inhibitors in advanced non-small cell lung cancer.

Authors:  Hazem I Assi; Alice O Kamphorst; Nour M Moukalled; Suresh S Ramalingam
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860

9.  Severe neurologic complications of immune checkpoint inhibitors: a single-center review.

Authors:  Sarah Mancone; Thomas Lycan; Tamjeed Ahmed; Umit Topaloglu; Andrew Dothard; William J Petty; Roy E Strowd
Journal:  J Neurol       Date:  2018-05-14       Impact factor: 4.849

Review 10.  MRI findings in Susac's syndrome.

Authors:  J O Susac; F R Murtagh; R A Egan; J R Berger; R Bakshi; N Lincoff; A D Gean; S L Galetta; R J Fox; F E Costello; A G Lee; J Clark; R B Layzer; R B Daroff
Journal:  Neurology       Date:  2003-12-23       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.